Genome Sequencing of the SARS-CoV-2 Delta (B.1.617.2) Variant of Concern Detected in Bangladesh

Banu, Tanjina Akhtar; Sarkar, Md. Murshed Hasan; Akter, Shahina; Goswami, Barna; Jahan, Iffat; Osman, Eshrar; Uzzaman, Mohammad Samir; Habib, Md. Ahasan; Mahmud, Abu Sayeed Mohammad; Uddin, MT; Nafisa, Tasnim; Molla, Md. Maruf Ahmed; Yeasmin, Mahmuda; Akram, Arifa; Khan, Mala

doi:10.1128/mra.00849-21

Cited by 6 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to CDC and WHO, the major VOCs are the Alpha variant (Lineage B.1.1.7), 55 Beta variant (Lineage B.1.351), 56 Gamma variant (Lineage P1), 57 Omicron variant (Lineage B.1.1.529), 58 and Delta variant (Lineage B.1.617.2). 59 The Epsilon variant (Lineage B.1.427 and B.1.429), Kappa variant (B.1.617.1), Mu variant (Lineage B.1.621), 28,60,61 Eta variant (B.1.525), Zeta variant (Lineage P.2), 57 Theta variant (P.3), lota variant (B.1.526), and Lambda variant (Lineage C.37) are the VOIs. 62 Currently, many subvariants of Omicron have been under scrutiny such as BA.5, BA.2.75, BJ.1, BA.4.6, XBB, BA.2.3.20, and XBB 1.5 in 2023.…”

Section: Variantsmentioning

confidence: 99%

“…The major classificational terms to denote the ever‐increasing types of mutant strains of SARS‐CoV‐2 virus are variants of concern (VOC) and variants of interest (VOI). According to CDC and WHO, the major VOCs are the Alpha variant (Lineage B.1.1.7), 55 Beta variant (Lineage B.1.351), 56 Gamma variant (Lineage P1), 57 Omicron variant (Lineage B.1.1.529), 58 and Delta variant (Lineage B.1.617.2) 59 . The Epsilon variant (Lineage B.1.427 and B.1.429), Kappa variant (B.1.617.1), Mu variant (Lineage B.1.621), 28,60,61 Eta variant (B.1.525), Zeta variant (Lineage P.2), 57 Theta variant (P.3), lota variant (B.1.526), and Lambda variant (Lineage C.37) are the VOIs 62 .…”

Section: Sars‐cov‐2: the Deadly Virusmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due to their compromised immune systems and the intricate interplay with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. This comprehensive review delves into the multifaceted relationship between COVID‐19 and cancer. Through an analysis of existing literature and clinical data, this review unravels the structural intricacies of the virus and examines its profound implications for cancer patients, thereby bridging the knowledge gap between virology and oncology. The review commences with an introduction regarding the COVID‐19 pandemic and cancer. It then transitions into a detailed examination of the SARS‐CoV‐2 virus and its variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 lineage). Subsequently, an insightful analysis of the impact of COVID‐19 on major cancer types (viz., Lung, Colon, Brain, and gastrointestinal cancer) is elaborated. Finally, the therapeutic avenues, oncological care, and management are discussed. The nexus between COVID‐19 and cancer adds a layer of complexity to patient care, emphasizing the importance of tailored approaches for those grappling with both conditions. Amid the landscape defined by the evolving viral strains, this review navigates through the multifaceted implications of COVID‐19 on cancer patients and underscores the significance of integrating virology and oncology.

show abstract

Section: Variantsmentioning

confidence: 99%

Section: Sars‐cov‐2: the Deadly Virusmentioning

confidence: 99%

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

show abstract

“…We hypothesized that this highly conserved region would not be as susceptible as other regions to acquisition of nonsynonymous changes within SARS-CoV-2 over time, and this has been observed as variants have emerged 18,19 . For example, the Omicron BA.1 baseline sequence differs in only 1 of 1094 amino acids (0.09%) (nsp12 P323L) from the Wuhan reference sequence in this conserved region, and so 99.1% of the PTEs are perfectly matched between the Omicron BA.1 and the Wuhan reference strain 18 .…”

Section: Development Of Rhad52covconsv Vaccinementioning

confidence: 99%

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

et al. 2022

View full text Add to dashboard Cite

The COVID-19 pandemic marks the third coronavirus pandemic this century (SARS-CoV-1, MERS, SARS-CoV-2), emphasizing the need to identify and evaluate conserved immunogens for a pan-sarbecovirus vaccine. Here we investigate the potential utility of a T-cell vaccine strategy targeting conserved regions of the sarbecovirus proteome. We identified the most conserved regions of the sarbecovirus proteome as portions of the RNA-dependent RNA polymerase (RdRp) and Helicase proteins, both of which are part of the coronavirus replication transcription complex (RTC). Fitness constraints suggest that as SARS-CoV-2 continues to evolve these regions may better preserve cross-reactive potential of T-cell responses than Spike, Nucleocapsid, or Membrane proteins. We sought to determine if vaccine-elicited T-cell responses to the highly conserved regions of the RTC would reduce viral loads following challenge with SARS-CoV-2 in mice using a rhesus adenovirus serotype 52 (RhAd52) vector. The RhAd52.CoV.Consv vaccine generated robust cellular immunity in mice and led to significant reductions in viral loads in the nasal turbinates following challenge with a mouse-adapted SARS-CoV-2. These data suggest the potential utility of T-cell targeting of conserved regions for a pan-sarbecovirus vaccine.

show abstract

“…The variant B.1.617.2 emerged for the first time in India in December 2020 [ 15 ]. Due to its rapid transmission, the World Health Organization (WHO) designated it as VOC Delta on May 11, 2021.…”

Section: Introductionmentioning

confidence: 99%

Computational design of medicinal compounds to inhibit RBD-hACE2 interaction in the Omicron variant: unveiling a vulnerable target site

Shahab

Akter

Sarkar

et al. 2023

Informatics in Medicine Unlocked

Self Cite

View full text Add to dashboard Cite

Genome Sequencing of the SARS-CoV-2 Delta (B.1.617.2) Variant of Concern Detected in Bangladesh

Abstract: We report the near-complete genome sequence and phylogenetic analysis of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant (B.1.617.2) strain. This variant is associated with increased transmission and immune evasion.

Cited by 6 publications

References 2 publications

COVID‐19 and cancer: Dichotomy of the menacing dilemma

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

Computational design of medicinal compounds to inhibit RBD-hACE2 interaction in the Omicron variant: unveiling a vulnerable target site

Contact Info

Product

Resources

About